GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncotelic Therapeutics Inc (OTCPK:OTLC) » Definitions » Accounts Receivable

Oncotelic Therapeutics (Oncotelic Therapeutics) Accounts Receivable : $0.02 Mil (As of Dec. 2023)


View and export this data going back to 1993. Start your Free Trial

What is Oncotelic Therapeutics Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Oncotelic Therapeutics's accounts receivables for the quarter that ended in Dec. 2023 was $0.02 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Oncotelic Therapeutics's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $-0.04.


Oncotelic Therapeutics Accounts Receivable Historical Data

The historical data trend for Oncotelic Therapeutics's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncotelic Therapeutics Accounts Receivable Chart

Oncotelic Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Accounts Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.15 0.02 0.02 0.02 0.02

Oncotelic Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Accounts Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.02 0.02 0.02 0.02

Oncotelic Therapeutics Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.


Oncotelic Therapeutics Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Oncotelic Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0.019/0*91
=

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Oncotelic Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Oncotelic Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(0.17+0.75 * 0.019+0.5 * 0-18.403
-0--0.519)/399.184
=-0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.


Oncotelic Therapeutics Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Oncotelic Therapeutics's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncotelic Therapeutics (Oncotelic Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
29397 Agoura Road, Suite 107, Agoura Hills, CA, USA, 91301
Oncotelic Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer with a focus on rare pediatric cancers, and addressing the current global pandemic. OT-101 is its lead immuno-oncology drug candidate. OT-101 also has activity against SARS-CoV-2. Its other products under pipeline are Artemisinin, CA4P, and Oxi4503. Currently, the company generates revenues from rendering services to other third-party customers for the development of certain drug products or in connection with certain out-licensing agreements.
Executives
Vuong Trieu officer: CHIEF EXECUTIVE OFFICER 4003 JIM BOWIE ROAD, AGOURA HILLS CA 91301
Saran Saund officer: CHIEF BUSINESS OFFICER C/O MATEON THERAPEUTICS INC., 29397 AGOURA RD SUTIE 107, AGOURA HILLS CA 91301
Amit B. Shah officer: CHIEF FINANCIAL OFFICER 10 AGUILA, ALISO VIEJO CA 92656
Chulho Park officer: CHIEF TECHNOLOGY OFFICER 701 GATEWAY BOULEVARD, SUITE 210, SOUTH SAN FRANCISCO CA 94080
Maida Anthony E Iii director 157 TECHNOLOGY DR, IRVINE CA 92618
Steven W King director
David Diamond director 29397 AGOURA RD., SUITE 107, AGOURA HILLS CA 91301
Fatih Uckun 10 percent owner, officer: Chief Medical Officer 701 GATEWAY BOULEVARD, SUITE 210, SOUTH SAN FRANCISCO CA 94080
Chao Hsiao 10 percent owner 701 GATEWAY BOULEVARD, SUITE 201, SOUTH SAN FRANCISCO CA 94080
Larn Hwang 10 percent owner C/O MARINA BIOTECH, INC., 17870 CASTLETON STREET, SUITE 250, CITY OF INDUSTRY CA 91748
Donald Rogers Reynolds director C/O WYRICK ROBBINS YATES & PONTON LLP, 4101 LAKE BOONE TRAIL, SUITE 300, RALEIGH NC 27607
Sandage Bobby W Phd director C/O 99 HAYDEN AVE, 1 LEDGEMONT CENTER, LEXINGTON MA 02173
Simon Pedder director 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Matthew M Loar officer: Chief Financial Officer 505 PENOBSCOT DR, REDWOOD CITY CA 94063
Pamela Ha officer: Controller 701 GATEWAY BOULEVARD, SUITE 210, SOUTH SAN FRANCISCO CA 94080

Oncotelic Therapeutics (Oncotelic Therapeutics) Headlines

From GuruFocus

Oncotelic Issues Year End Message to Shareholders

By Tiesvg Tiesvg 12-28-2022

Oncotelic Participating at Biotechgate Digital Partnering

By PurpleRose PurpleRose 08-17-2022

Oncotelic Publishes SITC Meeting 2022 Presentation Materials

By Value_Insider Value_Insider 11-16-2022

Oncotelic Launches PDAO SEC Chatbot

By sperokesalga sperokesalga 04-24-2023

Oncotelic Initiates Clinical Trials Evaluating OT-101 against Metastatic Pancreatic Cancer

By Stock market mentor Stock market mentor 01-25-2023

Oncotelic Reports Q3 2022 Compared to Q3 2021 Financial Results

By Value_Insider Value_Insider 11-21-2022

Oncotelic Publishes SNO 27th Annual Meeting Presentation Materials

By Value_Insider Value_Insider 11-30-2022